Archives

by in
Entry Author Date Location
Sage, Despite Industry-Wide Pullback, Scores $90M in Upsized IPO 07/17/14 Boston
Sage Therapeutics Readies IPO Pitch to Develop CNS Drugs 06/18/14 Boston
Sage Therapeutics Grabs $38M More For CNS Drugs 03/13/14 Boston
Sage Therapeutics Nabs $20M Series B From Third Rock, Arch 10/16/13 Boston
Sage Taps Former Shire Exec to Lead CNS Drugs Into Clinical Trials 08/14/13 Boston
East Coast Biotech Roundup: Cubist, Acetylon, Foundation, & More 08/02/13 Boston
Sage Wins $10M Grant to Push Fragile X Treatment Into Clinic 07/31/13 Boston
East Coast Life Sciences Roundup: Regeneron, Actavis, NPS, & More 05/24/13 Boston
San Diego Life Sciences Roundup: Topera, Afraxis, Trovagene, & More 05/03/13 San Diego
Sage Therapeutics Shifts Gears, Focuses on Rare Form of Epilepsy 04/17/13 Boston
Afraxis Licenses its Drug Compounds to Roche Subsidiary Genentech 01/29/13 San Diego
Roche Deal Gives Seaside a Leg Up in Autism Race 06/26/12 Boston
San Diego’s Afraxis Gets NIH Support to Develop Compound for Rare Fragile X Syndrome 09/26/11 San Diego
Boston’s Autism Mini-Cluster: New Drugs and Diagnostics Target Mysterious Brain Disorders 07/22/10 Boston
Torrey Pines Investment Raises $30 Million Toward $150M Target For Next Fund 03/23/10 San Diego
AFraxis CEO Outlines Biotech’s Success With Ultra-Lean Pre-Clinical R&D in Russia 02/26/10 San Diego
Carl Icahn Nominates Scripps Researcher to Biogen Idec Board, BrainCells Pursues New Drug Combo for Depression, Illumina Adds to Oxford Nanopore Investment, & More San Diego Life Sciences News 02/04/10 San Diego
San Diego’s aFraxis Studies Drug Candidates to Treat Fragile X Syndrome 02/03/10 San Diego
Autism Gets a Boost: Seaside Therapeutics Raises $30M To Develop First Drugs That Might Work 09/17/09 Boston
Page 1 of 1